Key pathway in end-stage prostate cancer tumor progression blocked

Jul 20, 2010

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.

Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth.

The findings, appearing online and in the August issue of Endocrinology, suggest that this step might one day provide a new avenue of therapy for patients with end-stage . Health care experts estimate that more than 2 million men in the U.S. have prostate cancer, with more than 27,000 deaths related to the disease in 2009.

"We were able to block the androgen response, which is a central pathway for ," said Dr. Nima Sharifi, assistant professor of internal medicine and the study's senior author.

End-stage prostate tumors typically are treated with hormones that suppress the levels of the androgens, or male hormones like , that cause prostate cancer cells to grow. Eventually, however, the tumors become resistant to this therapy and resume their growth.

Using prostate cancer cell lines, Dr. Sharifi and his colleagues found that the hormone dehydroepiandrosterone (DHEA) is converted by the tumors into androgens. By blocking the enzyme 3β-hydroxysteroid dehydrogenase (3βHSD), which is responsible for the first enzymatic step that is required to convert DHEA to androgens, researchers were able to shut down the tumors' lifeline.

"Enzymes in general can make great drug targets, so this process conceivably could be targeted for the development of new treatments for end-stage prostate cancer, which has limited therapeutic options right now," said Dr. Sharifi, an investigator in UT Southwestern's Harold C. Simmons Comprehensive Cancer Center. "The goal would be to develop a drug that targets that enzyme to be used for the advanced, incurable stage."

No standard treatments currently target this enzyme, but there is proven clinical evidence that this pathway is central to driving tumor progression.

Explore further: Results of new drug, ASP8273, show response in patients with treatment-resistant NSCLC

add to favorites email to friend print save as pdf

Related Stories

Scientists discover key event in prostate cancer progression

Jul 23, 2009

A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.

Recommended for you

New model of follow up for breast cancer patients

2 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

Immunotherapy set to revolutionise cancer treatment

4 hours ago

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.